BRIEF-Seres Therapeutics reports positive topline results from ser-287 phase 1b study in patients with ulcerative colitis
October 02, 2017 at 07:11 AM EDT
* Seres Therapeutics reports positive topline results from ser-287 phase 1b study in patients with ulcerative colitis